What was the main driver of Johnson & Johnson's sales growth in the third quarter of 2002?

The primary drivers of sales growth were strong performance in the Pharmaceutical segment, with a 16.3% increase, and the Medical Devices & Diagnostics segment, which grew 13.3%. Key pharmaceutical products like REMICADE, RISPERDAL, and TOPAMAX, along with growth in various medical device lines, contributed significantly to the overall increase.

Did Johnson & Johnson incur any significant charges in this reporting period?

Yes, the company incurred after-tax charges of approximately $150 million related to in-process research and development costs for the acquisition of Tibotec-Virco NV and $39 million for the acquisition of Obtech Medical AG. Additionally, a $150 million arbitration award was recognized in favor of Amgen related to a licensing agreement.

How did the company's stock repurchase program and dividend activity impact shareholders?

Johnson & Johnson completed a $5 billion stock repurchase program during the period, indicating a commitment to reducing share count and enhancing shareholder value. The company also declared a regular quarterly dividend of $0.205 per share, showing continued commitment to returning capital to shareholders.

What are the key risks or legal proceedings mentioned in this filing?

The company is involved in several significant legal proceedings, most notably numerous product liability cases related to PROPULSID, which has led to substantial damage claims and ongoing appeals. There are also patent infringement lawsuits concerning coronary stents and other key products, as well as ongoing discussions with regulatory authorities regarding reports of rare adverse events associated with EPREX. The company believes its reserves and insurance are adequate to cover potential liabilities.

JNJ 10-Q Filed Nov 12, 2002

Summary

Johnson & Johnson (JNJ) reported strong financial results for the third quarter and nine months ended September 29, 2002. The company experienced significant sales growth across its major segments, with notable contributions from Pharmaceuticals and Medical Devices & Diagnostics. Net earnings also showed a healthy increase, reflecting improved operational efficiencies and strategic acquisitions. Despite some legal proceedings and charges related to in-process research and development, the company's core business demonstrated robust performance, driven by key product lines and expanding market presence. For investors, the report highlights JNJ's ability to generate substantial revenue growth while effectively managing expenses. The company's strategic focus on innovation and acquisitions, particularly in the biopharmaceutical and medical device sectors, is evident in its expanding product portfolio and market penetration. While facing ongoing litigation and regulatory scrutiny in certain areas, JNJ appears to be prudently managing these risks and maintains a strong financial position, as evidenced by its cash flows and dividend payouts.

Key Highlights

1Consolidated sales increased by 12.7% to $9.08 billion for the third quarter and 11.6% to $26.90 billion for the nine months ended September 29, 2002.
2Net earnings for the third quarter rose by 12.8% to $1.73 billion, and for the nine months increased by 14.2% to $5.21 billion.
3The Pharmaceutical segment showed strong growth with a 16.3% increase in third-quarter sales, driven by key products like REMICADE, RISPERDAL, and TOPAMAX.
4Medical Devices and Diagnostics segment sales grew by 13.3% in the third quarter, bolstered by contributions from Cordis, DePuy, and Ethicon.
5The company completed a $5 billion stock repurchase program, demonstrating a commitment to returning value to shareholders.
6Acquisitions of Tibotec-Virco NV and Obtech Medical AG in the biopharmaceutical and medical device sectors are expected to enhance future growth.
7Despite a $150 million arbitration award in favor of Amgen, the company's overall financial performance remained strong, with net earnings per share showing positive growth.

JOHNSON & JOHNSON Quarterly Report for Q3 Ended Sep 29, 2002

Summary

Key Highlights

Frequently Asked Questions